ArticleOncoimmunology2023

Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status.

David Dora et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.